Read + Share
Amedeo Smart
Independent Medical Education
Fresan-Restituto D, Lacalle-Fabo E, Martin-Bujanda M, Sarobe-Carricas MT, et al. Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one. Rev Neurol 2023;76:213-216.PMID: 36908035
Email
LinkedIn
Facebook
Twitter
Privacy Policy